Hippo pathway gene mutations in malignant mesothelioma: Revealed by RNA and targeted exon sequencing

Journal of Thoracic Oncology

Volumn 10, Issue 5, 2015, Pages 844-851

  Miyanaga, Akihiko ^a,b   Masuda, Mari ^a   Tsuta, Koji ^c   Kawasaki, Kumiko ^d   Nakamura, Yuka ^a   Sakuma, Tomohiro ^d   Asamura, Hisao ^c   Gemma, Akihiko ^b   Yamada, Tesshi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d Mitsui Knowledge Industry Co   (Japan)

Author keywords

Fusion gene; Hippo pathway; LATS1; Malignant mesothelioma; Next generation sequencer

Indexed keywords

ANAPHASE PROMOTING COMPLEX SUBUNIT 2; E1A ASSOCIATED P300 PROTEIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GLUTATHIONE TRANSFERASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; LARGE TUMOR SUPPRESSOR 1; LARGE TUMOR SUPPRESSOR 2; MERLIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 5; PRESENILIN 1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 22; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 6; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; YES ASSOCIATED PROTEIN; CADHERIN; CELL CYCLE PROTEIN; FAT1 PROTEIN, HUMAN; FAT2 PROTEIN, HUMAN; HYBRID PROTEIN; LATS1 PROTEIN, HUMAN; LATS1-PSEN1 FUSION PROTEIN, HUMAN; LATS2 PROTEIN, HUMAN; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; ONCOPROTEIN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; PSEN1 PROTEIN, HUMAN; RASSF1 PROTEIN, HUMAN; RASSF2 PROTEIN, HUMAN; RASSF6 PROTEIN, HUMAN; SAV1 PROTEIN, HUMAN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAZ PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN; WWC1 PROTEIN, HUMAN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ALLELE; ANGIOGENESIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CHROMOSOME TRANSLOCATION; COLONY FORMATION; CONTROLLED STUDY; COPY NUMBER VARIATION; CYTOPLASM; DNA FLANKING REGION; EMBRYO; EXON; FUSION GENE; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; HIPPO SIGNALING PATHWAY; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; NEUROFIBROMATOSIS TYPE 2; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA SEQUENCE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; DNA SEQUENCE; EXOME; GENETICS; MESOTHELIOMA; METABOLISM; MUTATION; SEQUENCE ANALYSIS; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CADHERINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; EXOME; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MESOTHELIOMA; MONOMERIC GTP-BINDING PROTEINS; MUTATION; NEUROFIBROMIN 2; ONCOGENE PROTEINS, FUSION; PHOSPHOPROTEINS; PRESENILIN-1; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT FUSION PROTEINS; SEQUENCE ANALYSIS, DNA; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84938278946     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000493     Document Type: Article

References (25)

1. Carbone M, Ly BH, Dodson RF, Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2012 227 44 58
2. Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G, Simon GR., Malignant pleural mesothelioma: a comprehensive review. Cancer Control 2006 13 255 263
3. Tsao AS, Wistuba I, Roth JA, Kindler HL., Malignant pleural mesothelioma. J Clin Oncol 2009 27 2081 2090
4. Pan D., The hippo signaling pathway in development and cancer. Dev Cell 2010 19 491 505
5. Murakami H, Mizuno T, Taniguchi T, LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 2011 71 873 883
6. Sekido Y, Pass HI, Bader S, Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995 55 1227 1231
7. Bianchi AB, Mitsunaga SI, Cheng JQ, High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995 92 10854 10858
8. Harvey KF, Zhang X, Thomas DM., The Hippo pathway and human cancer. Nat Rev Cancer 2013 13 246 257
9. Masuda M, Chen WY, Miyanaga A, Alternative mTOR signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling. Mol Cell Proteomics 2014 13 1429 1438
10. Li H, Durbin R., Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009 25 1754 1760
11. McPherson A, Hormozdiari F, Zayed A, deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 2011 7 e1001138
12. Krzywinski M, Schein J, Birol I, Circos: an information aesthetic for comparative genomics. Genome Res 2009 19 1639 1645
13. Yu FX, Guan KL., The Hippo pathway: regulators and regulations. Genes Dev 2013 27 355 371
14. Stanger BZ., Quit your YAPing: a new target for cancer therapy. Genes Dev 2012 26 1263 1267
15. Visser S, Yang X., LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle 2010 9 3892 3903
16. Yang X, Yu K, Hao Y, LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1. Nat Cell Biol 2004 6 609 617
17. Yang X, Li DM, Chen W, Xu T., Human homologue of Drosophila lats, LATS1, negatively regulate growth by inducing G(2)/M arrest or apoptosis. Oncogene 2001 20 6516 6523
18. St John MA, Tao W, Fei X, Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 1999 21 182 186
19. Guo G, Chmielecki J, Goparaju C, Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res 2015 75 264 269
20. Overholtzer M, Zhang J, Smolen GA, Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006 103 12405 12410
21. Zender L, Spector MS, Xue W, Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006 125 1253 1267
22. Yokoyama T, Osada H, Murakami H, YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 2008 29 2139 2146
23. Xu MZ, Yao TJ, Lee NP, Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009 115 4576 4585
24. Wang L, Shi S, Guo Z, Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One 2013 8 e65539
25. Shitashige M, Satow R, Jigami T, Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. Cancer Res 2010 70 5024 5033